Professional development Vacancies

Overview of the recommendations adopted by the PRAC committee on signals discussed at the meeting of 23-26 November 2020

14.01.2021 1203 views

medicinal products containing pembrolizumab – vasculitis

Having considered the available evidence in EudraVigilance and in the literature, as well as the association between the use of pembrolizumab and vasculitis, the PRAC agreed that the registration certificate holder of the medicinal product Keytruda (Merck Sharp & Dohme B.V.) must, within 2 months, submit variations to update the instructions for medical use as indicated below (new text underlined, text for deletion):

In the "Special precautions for use" section of the instructions:

Other adverse reactions related to the immune system

The following clinically significant immune-related adverse reactions have been reported in clinical studies or in post-marketing use: uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain-Barré syndrome, myasthenic syndrome, hemolytic anemia, sarcoidosis, encephalitis, and myelitis and vasculitis (see the “Adverse reactions” and “Method of administration and dosage” sections).

Into the "Adverse Reactions" section of the leaflet:

Tabulated list of adverse reactions. Table 2: Adverse reactions in patients treated with pembrolizumab

  Monotherapy Combination with chemotherapy Combination with axitinib
Vascular disorders
Very common     hypertension
Common hypertension hypertension  
Uncommon   vasculitis  
Rare vasculitis    
Перелік лікарських засобів, що містять pembrolizumab і дозволені для медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 04.01.2021)

Link

https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-november-2020-prac-meeting_en.pdf